Skip to main content

Paediatric Haematology and Oncology Research

Paediatric Haematology and Oncology Research

We aim to provide the best possible treatment for every child with cancer.

Our Wolfson Childhood Cancer Research Centre opened in 2016. It brings together over 90 scientists and clinicians. They are supported by state-of-the-art facilities, including the Children's Cancer North Research Laboratories.

Our multi-disciplinary research teams work to advance our understanding of childhood malignancy. We translate these findings into improved treatments.

Our research encompasses:

  • characterisation of the molecular mechanisms of cancer development
  • exploration, preclinical and clinical evaluation of new treatment targets and concepts
  • biomarker development to improve patient management and deliver personalised therapies
Paediatric Oncology

Our vision

Advances over the last forty years have delivered good cure rates for many childhood cancers. But there are still many challenges.

A significant proportion of children will still succumb to their disease. Outcomes are not uniform, either within or between different disease types.

Current therapies are based on aggressive treatments with significant side effects. These impact the long-term quality of life for many surviving patients.

We are addressing these challenges by:

  • comprehensive characterisation of disease molecular pathology
  • exploring mechanisms of disease origin, progression and relapse
  • developing novel treatments with improved efficacy and fewer side effects
  • identifying and validating biomarkers to improve patient diagnosis, stratification and management
  • running clinical trials to test new treatment approaches

Our groups

We focus on six major areas:

Cancer can affect people of all ages.

Childhood solid tumours are distinct from those observed in adults and cure rates are significantly higher. Haematological cancers are responsible for considerable morbidity and mortality in all age groups. These cancers include acute and chronic leukaemia, lymphoma, myeloma and other malignant conditions

Our overarching aims are:

  • better understand the molecular mechanisms which drive the development of the disease
  • harness this information to improve the therapy and outcomes for children with cancer and patients with blood cancer

How we work

We use state-of-art technologies such as next generation sequencing and CRISPR gene editing to investigate the genetics and biology of these cancers.

We have also developed sophisticated classification models using molecular and clinical markers to:

  • design novel clinical trials
  • develop new treatment methods
  • improve outcomes for all patients

Impact of our work

Our work in childhood tumours and leukaemias has led to improved methods to prospectively identify children at high risk of disease relapse. They are now treated more effectively leading to improved survival.

Our work in adult haematological cancers focusses on understanding how disease develops and progresses at a molecular level. We use this information to develop effective treatment strategies with fewer side-effects that are better tolerated by older patients with co-morbidities.

Collaboration

To develop our research groups we collaborate extensively with national and international groups.

We also work with:

  • NHS colleagues at the Royal Victoria Infirmary and the Freeman Hospital
  • National Cancer Research Institute (NCRI) clinical study groups
  • Genomics England

Where we work

Most of our research takes place in the purpose-built Wolfson Childhood Cancer Research Centre. It opened in 2016. It brings together over 90 scientists and clinicians. We are supported by state-of-the-art facilities, including the NECCR Research Laboratories.

Principal research groupings

You may also be interested in:

https://research.ncl.ac.uk/lrcg/